CITALOPRAM, a selective serotonin reuptake inhibitor (SSRI), was approved by the Food and Drug Administration in 1998 as a safe and well-tolerated antidepressant; the use of it may result in rare and sometimes dangerous side effects. Diplopia is a rare adverse effect of CITALOPRAM that comes with double vision and disrupts daily living. Currently, only two cases of CITALOPRAM-related diplopia have been internationally reported. The current paper presents a third reported case of diplopia following CITALOPRAM use in a healthy subject. A 47-year-old man involved in an accident was subsequently affected by serious depression. Following 6 months of a 40-mg daily dose of CITALOPRAM, the patient complained of itchy irritated eyes and double vision symptomatic of diplopia. He was referred to an eye specialist, who confirmed no apparent problems following an examination of the eye. After a decrease in the dose of CITALOPRAM, the eye symptoms steadily decreased and eventually disappeared. The rapid disappearance of diplopia subsequent to the discontinuing use of CITALOPRAM suggests an association between the adverse reaction and the medicine. As a result, it is recommended that physicians inform patients of the possibility of induction of diplopia related to the use of CITALOPRAM and other SSRIs. In the future, the prescription of SSRIs at higher doses may be ordered with and on the recommendation of patients, who have been aware of the risks of the drug.

Introduction: We evaluated the efficacy of CITALOPRAM and sertraline in the treatment of premature ejaculation (PE).Materials and Methods: Of 101 married men with PE, 80 were eligible and consented to participate in this randomized controlled trial. Erectile dysfunction and administration of drugs for the treatment of PE were the exclusion criteria. The patients were evaluated using index of premature ejaculation (IPE) questionnaire and were randomly assigned into groups 1 (sertraline) and 2 (CITALOPRAM). They received one of these drugs for 8 weeks and then were re-evaluated by the IPE. Pretreatment and posttreatment results were compared within and between the study groups. Results: A total of 80 patients entered and completed the study. The mean age of the patients was 38.4 ± 7.7 in group 1 and 37.5 ± 6.9 in group 2 (P = .60). The mean pretreatment IPE scores were 21.4 ± 1.8 and 20.9 ± 1.3 in the patients of groups 1 and 2, respectively (P = .23). After 8 weeks, significant improvement was seen in both groups in terms of the IPE questionnaire results (39.8 ± 1.4; P < .001 and 39.5 ± 2.9; P < .001, respectively). However, the treatment response was not different between the 2 groups (P = .50). No serious adverse effects were detected in any of the patients and both drugs were tolerated well. Conclusion: CITALOPRAM and sertraline are safe and effective in patients with PE. Additionally, we failed to find any difference between the effects of these two drugs in the treatment of this condition.

Statement of problem: Psychosocial factors are thought to play a role in burning mouth syndrome (BMS) and several therapeutic approaches for BMS are based on this consideration. Purpose: This paper evaluated the efficacy of the combined systemic administration of CITALOPRAM and clonazepam, as anti- depressant and anti- anxiety drugs, in the management of burning mouth syndrome and reduction of the burning sensation.Materials and Method: In this cross- sectional study, 80 subjects suffering from idiopathic burning mouth syndrome were enrolled. The patients underwent a thorough clinical examination. Oral symptoms before and after treatment were assessed using a Visual Analogue Scale. The mean duration of burning in our patients was 7 months. Systemic combination of CITALOPRAM (20 mg/ daily) and clonazpam (0.25 mg/ daily) was prescribed for all of them for 8 weeks. Then, the data were analysed, using Student’s t-test.Results: Of the 62 patients who completed the protocol, 38 reported complete remission of the oral burning sensation. However, 20 patients reported a little improvement, and four of them reported no improvement.Conclusion: These data suggest that citaloperam with colonazpam is a effective in patients with BMS.

In this study, we used the computational process by DFT with the B3LYP/6-311+G (d, p) quantum method to discover the reactivity properties and dope and determine the adsorption behavior of CITALOPRAM on C60 (ih) as anti-depression drug carriers in the gas phase. We calculated chemical structural parameters such as dipole momentum) 3. 7193D) and electronic parameters (σ(6. 45), µ(-2. 70), ω(16. 5), χ(2. 70) and η(1. 53)) which can determine the chemical reactivity of CITALOPRAM. According to the calculated HOMO(-4. 25eV) and LUMO(-1. 15eV) energy value, CITALOPRAM is a stable and chemical active compound and has chemical reactivity. It has six active sides, which lead to adsorb on C60 nanocage as a drug carrier. This Surface adsorption helps CITALOPRAM transfer to biological systems much better.